ENO1 and cancer: In over 70% of cancer cases, ENO1 was found to be over-expressed, which accelerated the glycolytic pathway and contributed to several tumor progression activities, such as (1) inducing angiogenesis, (2) sustaining proliferative signaling, (3) activating invasion and metastasis, (4) deregulating cellular energetics, and (5) avoiding immune destruction.